GHK-Cu

100mg Vial

2 July 2026Updated 10 October 2026

GHK-Cu

Overview Research13 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for GHK-Cu.

Create free account Member login

Full range of benefits for GHK-Cu

Promotes collagen and elastin synthesis by dermal fibroblasts

Supports wound healing and skin repair processes

Modulates gene expression involved in tissue remodelling

Regulates matrix metalloproteinases and TIMPs for ECM balance

Exhibits anti-inflammatory effects in skin cell models

Supports antioxidant defenses and reduces oxidative damage

Promotes angiogenesis and microvascular repair in wound models

May stimulate hair follicle activation and hair growth

Associated with improved skin firmness and elasticity

Contributes to scar remodelling and improved skin texture

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 13 known interactions

Synergistic(3)Compatible(3)Monitor(3)Avoid(4)

Not recommended for concurrent use

Wilson disease (hereditary copper accumulation)

Patients with Wilson disease have impaired copper handling and should be carefully evaluated before any copper‑containing therapy due to risk of accumulation.

Copper chelators (e.g., penicillamine, trientine)

Chelating agents will antagonize the activity of copper peptides and may reduce efficacy or alter systemic copper balance, so co‑use requires specialist review.

High‑dose zinc therapy

Chronic high‑dose zinc intended to lower copper (e.g., for Wilson disease) can induce copper deficiency and should prompt re‑evaluation before initiating GHK‑Cu.

Pregnancy and breastfeeding

There are limited safety data for GHK‑Cu in pregnancy and lactation, so benefits versus risks should be carefully considered and discussed with the patient.

All interaction categories

Synergistic (3)

Ascorbic acid (Vitamin C): Vitamin C is a cofactor for collagen hydroxylases and can enhance GHK-Cu–mediated stimulation of collagen synthesis and wound repair.
Platelet-rich plasma (PRP): PRP provides growth factors that complement GHK-Cu’s pro‑regenerative and angiogenic activity to promote tissue repair.
Hyaluronic acid (topical or injectable): Hyaluronic acid supplies extracellular matrix hydration and scaffolding that can augment the tissue remodeling effects of GHK-Cu.

Compatible (3)

Topical sunscreens and emollients: Sunscreens and standard moisturizers have neutral co‑administration profiles with GHK-Cu and require no special adjustment.
Botulinum toxin (aesthetic use): Botulinum toxin for muscle relaxation is commonly co‑administered in cosmetic protocols and does not have known pharmacologic antagonism with GHK-Cu.
Standard oral multivitamin (excluding high‑dose zinc): Routine multivitamins that do not contain high doses of zinc are generally compatible with GHK-Cu without special precautions.

Monitor (3)

Systemic copper supplementation: Concurrent systemic copper increases total body copper exposure and warrants monitoring of serum copper and ceruloplasmin to avoid excess.
Oral zinc supplements: High‑dose zinc can impair copper absorption and may require monitoring of copper status (serum copper/ceruloplasmin) and adjustment of supplementation.
Systemic corticosteroids: Systemic steroids inhibit inflammatory and reparative processes, so clinical wound healing and response to GHK-Cu should be monitored and steroid dosing reviewed.

Avoid (4)

Wilson disease (hereditary copper accumulation): Patients with Wilson disease have impaired copper handling and should be carefully evaluated before any copper‑containing therapy due to risk of accumulation.
Copper chelators (e.g., penicillamine, trientine): Chelating agents will antagonize the activity of copper peptides and may reduce efficacy or alter systemic copper balance, so co‑use requires specialist review.
High‑dose zinc therapy: Chronic high‑dose zinc intended to lower copper (e.g., for Wilson disease) can induce copper deficiency and should prompt re‑evaluation before initiating GHK‑Cu.
Pregnancy and breastfeeding: There are limited safety data for GHK‑Cu in pregnancy and lactation, so benefits versus risks should be carefully considered and discussed with the patient.